The prolongation of A-V transmission time that occurs with increasing rates of right atrial pacing has been used to study the effect of ouabain and of ouabain plus atropine on A-V nodal conduction in 14 patients with normal A-V nodes. Drugs were injected into the superior vena cava or pulmonary artery over a 1-to 2-min period. Atropine in a dose of 0.02 mg/kg shortened A-V conduction time by an average of 0.112 sec; ouabain alone in a dose of 0.01 mg/kg lengthened A-V conduction time by 0.053 sec. Ouabain given after large doses of atropine did not prolong A-V conduction at any paced rate. Thus, in these resting patients with normal A-V nodal function, usual digitalizing dosages of ouabain did not have an extravagal or anriadrenergic effect on A-V nodal conduction.
atrial fibrillation. Since the work of Gold (3, 4 ) , it has generally been accepted that digitalis has both vagal and extravagal actions in man. The relationship of extravagal to vagal effect on A-V conduction has not been established, however, in patients with minimal or no cardiac disability.
Using cats, McLain, Kruse, and Redick (5) concluded that an extravagal influence of digitoxin-induced bradycardia was due to a direct effect of digitoxin on autorhythmic sinus nodal cells. A series of experiments in dogs by MeVidez, Aceves, and MeYidez (6) showed that the extravagal action of digitalis is primarily to counteract the effect of adrenergic substances on the A-V transmission system.
The occurrence of a linear relationship between the electrocardiographic P-R intervals and heart rate when rate is divorced from the Key: MS = mitral stenosis; Coarct = coarctation of aorta; N = normal heart; VSD = ventricular septal defec AS = aortic stenosis; ASD = atrial septal defect.
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Data Obtained wtih Atrial Pacing with and without Atropine and Ouabain
CARLETON, MILLER, GRAETTINGER
•Number of observations. autonomic system by atrial pacing has provided an opportunity to study A-V nodal function in man (7, 8) . In the present study the effect of ouabain on the A-V transmission time, and the interaction of ouabain and atropine have been examined in patients with no or minimal heart disease.
Material and Methods
In each of 14 patients, who had given informed consent, right atrial pacing and pharmacologic interventions were performed during diagnostic cardiac catheterization (13 patients) or hepatic venous catheterization. Six individuals had systolic murmurs without detectable cause and were considered to have normal hearts; 2 patients had a small ventricular septal defect with normal pulmonary arterial pressures and left to right shunts demonstrable only by indicator-dilution techniques; 1 had a left to right shunt through a secundum atrial septal defect; 1 had a 15 mm Hg gradient across a coarctation of the descending aorta; 2 had mild mitral stenosis with calculated mitral valve areas of 2.0 and 1.8 cm 2 , respectively; 1 had moderate aortic stenosis (calculated valve area, 1.4 cm 2 ), and 1 had Laennec's cirrhosis. None of these individuals had cardiac symptoms; none had ever recognized cardiac arrhythmias; and none had ever received a digitalis preparation. All were considered to have normal A-V nodal function. Data about them and their control electrocardiograms while in sinus rhythm are presented in Table 1 .
The patients were studied supine in the postabsorptive state. Meperidine (50 to 75 mg) and sodium pentobarbital (75 to 100 mg) had been administered 2 to 4 hours earlier. An electrode catheter was placed in the right atrium so that its tip was in contact with the right lateral atrial wall. A position was used which prevented dislocation of the tip during deep breathing or coughing; the site of atrial stimulation did not change throughout any study.
The external terminals of the electrode catheter were connected to a battery powered pacemaker. Atrial pacing was conducted with 2-msec impulses at approximately twice the usual 1 volt threshold. Electrocardiographic recordings were made at 25 mm/sec with an optical galvanometer-photographic paper system of the lead, usually lead II, which best displayed the pacemaker impulse, the P wave and the QRS complex. In each study period, the atria were paced for 10 to 15 sec at each of many different rates between the intrinsic sinus rate and approximately 150/min. Measurements were made of the R-R interval, converted to heart rate, and of the A-V transmission time to the nearest 0.01 sec. The latter was measured as the time between the onset of the pacemaker impulse and the onset of QRS; for this reason, the shortest "P-R" intervals recorded were slightly longer than the P-R intervals of the baseline electrocardiogram. The dose of ouabain, U.S.P. was 0.01 mg/kg. The first dose of atropine was 0.02 mg/kg; the second was always 0.4 mg. All drugs were administered into the superior vena cava or into the pulmonary artery during a 1-to 2-min period. The onset of action of each drug was tested by brief electrocardiographic recordings at 5-min intervals after ouabain and by continuous recording for 3 min after atropine. Ouabain given alone (4 patients) prolonged A-V conduction progressively. The first change was noted at 5 min (3 patients) or 10 min (1 patient); the effect increased through 20 min (2 patients) or 25 min CircuUiioo Rtsirch, Vol. XX. M.rcb 1967 (2 patients) . The values at 25 and 30 min after administration were the same as at 20 and 25 min. Atropine (10 patients) had its initial effect within 30 sec; the effect became stable within 3 min and then remained for at least 10 min. Therefore, recordings for the study periods were begun 30 min after ouabain or 5 min after a dose of atropine.
The experimental protocol differed for two groups of patients. The 4 patients of group I received ouabain alone. The 2 patients of group Ila received atropine prior to ouabain. The 8 subjects of group lib received a second dose of atropine 30 min after the initial atropine and 25 min after the ouabain.
Tabulations of data for each study period in each patient were subjected to least squares regression analysis. Each analysis provided an equation of the form y = ax + b, where a is the slope and b is the y intercept for the regression line. These calculated coefficients are presented in Table 1 . The best statistical estimate of the P-R interval corresponding to any paced rate may be calculated from each equation; for the present analysis, paced rates of 120 and 140/ min were chosen. The estimated P-R intervals obtained during similar study periods were then averaged. The group means of these P-R intervals were compared using Student's t test.
Results
No arrhythmias occurred as a result of atrial pacing in the control studies. The sinus nodal rate accelerated from an average of 73.3 to 119.7 beats/min with atropine. Ouabain without atropine was associated with variable slight changes in sinus rate. Ouabain after atropine (group lib) also variably affected the sinus rate; in 1 patient the rate increased, in 2 it remained unchanged, and in 5 it decreased (average change, decrease of 3 beats/min). Patient A.A. developed a brief period of A-V nodal tachycardia 30 min after ouabain; no other arrhythmias occurred during these studies.
The sinus node of each patient required approximately 3 sec in which to accelerate gradually to a stable rate when rapid artificial pacing was stopped. This "rewarming" time was not modified by ouabain or by atropine. There were no measurable differences in the contour or duration of the P waves after ouabain or after atropine. No latency between the stimuli and P waves was measurable in any tracings.
The P-R interval lengthened linearly with increased rate in each study. A representative graph is shown for patient R.W. in group lib (Fig. 1) . The calculated results are presented in Table 1 . In the control studies the average P-R value increased from 0.269 sec (SE = 0.14) at a rate of 120 beats/min to 0.299 sec (SE = 0.14) at a rate of 140 beats/ min. The control data from the 7 patients with normal hearts were separately analyzed and were not significantly different from those of the other 7 patients.
The administration of ouabain alone was uniformly associated with prolongation of the A-V transmission time at any paced rate. The change between the control values and those with ouabain alone at a paced rate of 120/ min are shown in Figure 2 ; the average increment in P-R interval was 0.048 (range 0.031 to 0.081) sec. At a paced rate of 140/ min, the average increment was 0.057 (range 0.039 to 0.101) sec. Thus, in a dosage slightly above the usual digitalizing amount, ouabain significantly prolonged A-V transmission time.
Each patient in group II received atropine prior to the administration of ouabain. Five minutes later the average regression slope had changed significantly from 0.00152 to 0.00090 (P < 0.05). The average y intercept decreased slightly. The average P-R interval decreased from 0.279 to 0.188 sec (P<.001) at paced rate of 120/min (Fig. 2) and from 0.309 to 0.205 sec (P<.001) at a rate of 140/min. The 2 patients of group Ha received no supplemental atropine. Thirty minutes after ouabain and 35 min after atropine, their P-R values at any rate had returned approximately halfway toward their control values. This suggested either that ouabain had a major extravagal effect at the dosage used, or that the atropine effect had lessened within the elapsed 35 min.
Each of the 8 patients of group lib, therefore, received a supplemental dose of 0.4 mg of atropine before the recordings made 30 min after ouabain. Comparison between the atropine alone and the atropine plus ouabain studies in these 8 patients can be seen in Figure 2 .
The largest individual change between the atropine alone and the atropine plus ouabain study at a rate of 120/min was a shortening of P-R interval by 0.006 sec; 2 patients showed P-R prolongation by 0.005 sec. The average value of 0.188 sec with atropine alone was not significantly different from the value of 0.189 sec obtained with atropine plus ouabain. At a rate of 140/min, the largest change in P-R interval was prolongation by 0.003 sec; the average values were 0.205 and 0.206 sec, respectively. Thus, the mean P-R intervals, the slopes, and the y intercepts of the regression lines were not significantly influenced by ouabain when the patients were fully atropinized.
Discussion
The results presented confirm many previous observations that A-V conduction time is prolonged when atrial rate is increased without autonomic nervous system stimulation (7, 8, 9) . Parasympatholytic doses of atropine caused the expected acceleration in A-V conduction.
The dosage of ouabain used was moderately above that usually recommended for digitalization (10) and above that known to cause an inotropic effect in man (11) . It was, however, insufficient to cause evidence of digitalis intoxication with the probable exception of nodal tachycardia in patient A.A. Neither atropine nor ouabain produced detectable changes in atrial depolarization. For this reason, changes in P-R interval are considered to represent altered A-V nodal conduction velocity almost exclusively. The observations in the 4 patients of group I demonstrate a clear prolongation of A-V nodal transmission time after ouabain. With the assumption that a comparable ouabain effect occurred in the last 8 patients, the effect of atropine is interpreted to show that the prolonged A-V transmission time produced by these doses of ouabain was entirely mediated by the vagus nerves in these persons with normal A-V nodal function.
The explanation for the absence of an extravagal component of digitalis action in these patients must be speculative. The evidence obtained previously in experimental animals (6) and in man (3, 4) clearly indicates both vagal and extravagal actions of digitalis preparations. The latter effect has been shown to be largely antiadrenergic in character in dogs (6) . The degree of this antiadrenergic action should be a function of the existing level of sympathetic nervous system activity. In the patients that Gold et al. (3) studied, 8 of 9 had "an advanced degree of heart failure" and may be presumed to have had a high level of adrenergic activity against which digitalis could act, yielding evidence of a major extravagal role. In contrast, none of the present 14 patients, who were studied at rest, had evidence of heart failure. Finally, the dosages used by Gold were sufficiently large to produce toxicity in 4 of the 9 patients. These differences may be largely responsible for the lack of an extravagal influence of ouabain in the present patients.
Finally, the present data reinforce an explanation of why larger doses of digitalis are required to control the ventricular rate in atrial fibrillation in patients who are physically active, in congestive failure, or under other stress, than are necessary in compen-sated patients at rest. The present unstressed patients demonstrated that the entire effect of ouabain on the A-V node was mediated by vagal mechanisms. Parasympathetic activity decreases and sympathetic activity increases with certain types of stress, providing the setting for an extravagal effect of digitalis and increasing the required dosage for equivalent control of ventricular rate.
